Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health renewed the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule to a notice published in the New Zealand Gazette, 8 April 2010, No. 40, page 1159.
This corrigendum amends the notice by replacing the entry with the following renewal of provisional consent to the distribution of a medicine.
Schedule
Product: HyperHep B
Active Ingredient: Hepatitis B immunoglobulin, human 220IU/mL
Dosage Form: Solution for injection
New Zealand Sponsor: EastMed Pharmacy Limited t/a EastMed Logistics
Manufacturer: Talecris Biotherapeutics Inc, Clayton, United States of America
Note: This renewed consent is valid for two years from 8 May 2010.
Dated this 13th day of May 2010.
STEWART JESSAMINE, Acting Deputy Director-General, Regulation and Governance Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).